摘要
2016年世界卫生组织(WHO)分类修订版中把与染色体重排无关的Myc和Bcl-2蛋白的过度表达定义为双表达淋巴瘤(double expressor lymphoma,DEL),但其并非一个独立的诊断类别,仍属于DLBCL非特指型(DLBCL not otherwise specified,DLB⁃CL-NOS)。随着对该疾病认识的不断深入,对DEL患者的预后分析及治疗方案等有很多研究,如Myc和Bcl-2蛋白过表达不同阳性阈值、P53蛋白过表达、CD5蛋白过表达及血清白蛋白水平对其预后的判断价值,以及强化化疗、造血干细胞移植、靶向治疗、免疫治疗等治疗方法的研究探索。本文旨在对DEL患者的预后因素及治疗进展进行综述。
In the revised 2016 WHO Classification of Lymphoid Neoplasms,double expressor lymphoma(DEL)is defined as a diffuse large B-cell lymphoma(DLBCL)with increased expression of Myc and Bcl-2 proteins which is uncorrelated with chromosomal rearrangements.DEL is not an independent diagnostic category.It is still considered to be a DLBCL not otherwise specified(DLBCL-NOS).Many studies on the prognosis and treatment of DEL patients have deepened our understanding of this disease,including studies of the impact of different cut-offs for Myc and Bcl-2 protein overexpression;the prognostic value of TP53,CD5,and serum albumin;and explorations of intensive chemotherapy,hematopoietic stem cell transplantation,targeted therapies,immunotherapies,etc.The purpose of this review is to discuss the prognostic factors and current therapeutic approaches for patients with DEL.
作者
逯亚晓
张婷婷
王先火(综述)
张会来(审校)
Yaxiao Lu;Tingting Zhang;Xianhuo Wang;Huilai Zhang(Department of Lymphoma,Tianjin Medical University Cancer Institute and Hospital,Sino-US Center for Lymphoma and Leukemia Research,National Clinical Research Center of Cancer,Tianjin Key Laboratory of Cancer Prevention and Therapy,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2021年第9期472-477,共6页
Chinese Journal of Clinical Oncology
基金
天津市自然科学基金项目(编号:19JCYBJC26500)资助。
关键词
双表达淋巴瘤
预后
治疗
double expressor lymphoma(DEL)
prognosis
treatment